Seroprevalence survey of anti-SARS-CoV-2 antibody and associated factors in South Africa: Findings of the 2020-2021 population-based household survey.
Journal
PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
20
12
2022
accepted:
13
08
2023
medline:
25
9
2023
pubmed:
25
9
2023
entrez:
25
9
2023
Statut:
epublish
Résumé
Population-based serological testing is important to understand the epidemiology and estimate the true cumulative incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to inform public health interventions. This study reports findings of a national household population SARS-CoV-2 serosurvey in people 12 years and older in South Africa. This cross-sectional multi-stage random stratified cluster survey undertaken from November 2020 to June 2021 collected sociodemographic data, medical history, behavioural data, and blood samples from consenting participants. The samples were tested for SARS-CoV-2 antibodies using the Roche ElecsysAnti-SARS-CoV-2 chemiluminescence immunoassay (CLIA) Total Antibody Test. The survey data were weighted by age, race, sex, and province with final individual weights benchmarked against the 2020 mid-year population estimates and accounted for clustering. Descriptive statistics summarize the characteristics of participants and seroprevalence. Logistic regression analyses were used to identify factors associated with seropositivity. From 13290 survey participants (median age 33 years, interquartile range (IQR) 23-46 years), SARS-CoV-2 seroprevalence was 37.8% [95% Confidence Interval (CI) 35.4-40.4] and varied substantially across the country's nine provinces, and by sex, age and locality type. In the final adjusted model, the odds of seropositivity were higher in women than in men [aOR = 1.3 (95% CI: 1.0-1.6), p = 0.027], and those living with HIV (self-report) [aOR = 1.6 (95% CI: 1.0-2.4), p = 0.031]. The odds were lower among those 50 years and older compared to adolescents 12-19 years old [aOR = 0.6 (95% CI: 0.5-0.8), p<0.001] and in those who did not attend events or gatherings [aOR = 0.7 (95% CI: 0.6-1.0), p = 0.020]. The findings help us understand the epidemiology of SARS-CoV-2 within different regions in a low-middle-income country. The survey highlights the higher risk of infection in women in South Africa likely driven by their home and workplace roles and also highlighted a need to actively target and include younger people in the COVID-19 response.
Identifiants
pubmed: 37747851
doi: 10.1371/journal.pgph.0002358
pii: PGPH-D-22-02017
pmc: PMC10519586
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0002358Informations de copyright
Copyright: © 2023 Moyo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests. All authors were Funded by the Solidarity Fund and the Human Sciences Research Council. The National Institute for Communicable Diseases, South Africa, funded testing with the Roche assay Sizulu Moyo, Leickness C.S. Simbayi, Khangelani Zuma, Nompumelelo Zungu, Edmore Marinda E, Sean Jooste, Whadi-ah Parker, Shandir Ramlagan, Inbarani Naidoo, Musawenkosi Mabaso designed and led the study and were and are still employed by the Human Sciences Research Council. Mirriam Fortuin Beverley Singh, Adrian Puren led and conducted the laboratory testing and were and are still employed by the National Institute for Communicable Diseases, South Africa.
Références
Lancet HIV. 2022 Jul;9(7):e486-e495
pubmed: 35561704
MMWR Morb Mortal Wkly Rep. 2020 Oct 16;69(41):1497-1502
pubmed: 33056953
Influenza Other Respir Viruses. 2022 Jan;16(1):7-13
pubmed: 34611986
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
JAMA Netw Open. 2022 Jul 1;5(7):e2222126
pubmed: 35838670
Clin Microbiol Infect. 2021 Nov;27(11):1695.e7-1695.e12
pubmed: 34245905
Transfusion. 2021 Sep;61(9):2677-2687
pubmed: 34121205
BMC Infect Dis. 2022 Jan 9;22(1):41
pubmed: 35000580
PLoS One. 2021 Mar 10;16(3):e0242587
pubmed: 33690600
Int J Infect Dis. 2020 Dec;101:314-322
pubmed: 33045429
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Cell Host Microbe. 2020 Oct 7;28(4):516-525.e5
pubmed: 32941787
Res Sq. 2021 Feb 12;:
pubmed: 33594353
Lancet. 2020 Aug 22;396(10250):514-515
pubmed: 32645348
Public Health Action. 2021 Jun 21;11(2):58-60
pubmed: 34159063
Emerg Infect Dis. 2021 Dec;27(12):3020-3029
pubmed: 34477548
Int J Infect Dis. 2022 May;118:256-263
pubmed: 35306205
Clin Infect Dis. 2021 Oct 5;73(7):e2005-e2015
pubmed: 32860699
Int J Epidemiol. 2022 May 9;51(2):404-417
pubmed: 34718591